Marc Dunoyer

CEO, Alexion and Chief Strategy Officer, AstraZeneca · AstraZeneca

Pharmaceuticals

Marc Dunoyer is Alexion’s chief executive officer and AstraZeneca’s chief strategy officer. He previously served as AstraZeneca’s CFO after a pharmaceutical career that included GSK, Hoechst Marion Roussel and Roussel Uclaf.

Last reviewed: Nov 16, 2026

Executive Summary

Marc Dunoyer is Alexion’s chief executive officer and AstraZeneca’s chief strategy officer. He previously served as AstraZeneca’s CFO after a pharmaceutical career that included GSK, Hoechst Marion Roussel and Roussel Uclaf.

Career Highlights

  • Became Alexion CEO in August 2021 following AstraZeneca’s acquisition.
  • Served as AstraZeneca CFO from November 2013.
  • Previously combined GSK rare-disease leadership with its Japanese chairmanship.

Professional Journey

Dunoyer qualified in accountancy before entering the pharmaceutical industry at Roussel Uclaf in Paris in the 1970s. He later led its Japanese and Asia Pacific operations and returned to France as managing director of its Global Pharmaceuticals Division. His academic qualifications include an MBA from HEC Paris and a law bachelor’s degree from Paris University.

In 1995 he became president and CEO for Asia Pacific and Japan at Hoechst Marion Roussel. He moved to Glaxo Wellcome’s Japanese business, becoming its representative director and president in March 2000 and president of GlaxoSmithKline KK in January 2001 after the merger.

Dunoyer joined GSK’s corporate executive team in 2003 and became regional president for Asia Pacific and Japan in May 2008. In 2010 he combined the Japanese chairmanship with leadership of GSK’s newly established Rare Diseases Unit.

He joined AstraZeneca in June 2013 to lead Global Portfolio & Product Strategy. On November 1 that year, he became CFO and an executive director. Following the group’s acquisition of Alexion in July 2021, he moved to chief executive of its rare-disease business in August, also becoming AstraZeneca’s chief strategy officer.

His other corporate responsibilities include chairing AstraZeneca KK. At JCR Pharmaceuticals, he served as an outside director from June 2010 to April 2013 and returned to its board in June 2023. JCR’s 2026 shareholder notice also records his Cellectis directorship from December 2023.

Education

Master of Business Administration — HEC Paris.

Bachelor of Law — Paris University.